Known, unknown, and estimated
- Known: FDA prescribing information reports an approximately one-week half-life for semaglutide.
- Known: product, route, amount, timing, and schedule status are distinct record fields.
- Unknown: exact personal exposure and the cause of any logged symptom.
- Estimate: a modeled curve describes assumptions, not measured blood concentration.
What the live search results reveal
The live United States Google results for “semaglutide tracker app” feature Shotsy, App Store listings, Glapp, MeAgain, and comparison content. The winning pages make the product-compound relationship explicit and immediately show the tracking jobs they solve. This page does that without making treatment claims.
Keep formulation and route explicit
Semaglutide exists in injectable and oral products. A useful record names the exact product and route rather than storing only “semaglutide.” The weekly injectable half-life does not make every formulation's absorption pattern identical.
Event history
Record product, route, amount, unit, date, time, site, and status.
Weekly schedule
Separate planned events from completed, delayed, and skipped events.
Weight and symptoms
Preserve timestamped observations without asserting causality.
Estimated curve
Use published half-life assumptions only as an explanatory model.
Why a tracker is not a dose adviser
Medication instructions and missed-dose rules belong to the current prescribing information and the prescribing clinician. The app's role is to preserve a clear record. It should not turn a modeled curve, weight trend, or symptom log into an automated treatment recommendation.
Primary sources: FDA Ozempic prescribing information, FDA Wegovy prescribing information, and Halflife App Store listing.
Keep the complete record in one place
Halflife - Peptide & GLP-1 Log organizes logs, schedules, vial inventory, injection sites, symptoms, and clearly labeled model estimates on iPhone.
Download Halflife - Peptide & GLP-1 Log